Methadone and buprenorphine for the management of opioid dependence in pregnancy

Drugs

Volumn 72, Issue 6, 2012, Pages 747-757

  Jones, Hendrée E ^a,b   Finnegan, Loretta P ^c,d   Kaltenbach, Karol ^e  

^a RTI INTERNATIONAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Finnegan Consulting LLC   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Buprenorphine; Methadone; Opioid abuse; Pregnancy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BUPRENORPHINE; GAMMA GLUTAMYLTRANSFERASE; ILLICIT DRUG; METHADONE; OPIATE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFICACY; FETUS HEART; FETUS MONITORING; FETUS MOVEMENT; FETUS OUTCOME; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART RATE VARIABILITY; HUMAN; HYPERACTIVITY; INFECTION; LIVER TOXICITY; LOOSE FECES; NEONATAL RESPIRATORY DISTRESS SYNDROME; NONHUMAN; OPIATE ADDICTION; PREGNANCY; PREGNANT WOMAN; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SNEEZING; TREATMENT OUTCOME; TREMOR; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; BUPRENORPHINE; FEMALE; HUMANS; INFANT, NEWBORN; METHADONE; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84859887561     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11632820-000000000-00000     Document Type: Review

References (79)

1. Broussard CS, Rasmussen SA, Reefhuis J, et al. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol 2011; 204 (4): 314.e1-11
2. Cleary BJ, Donnelly JM, Strawbridge JD, et al. Methadone and perinatal outcomes: a retrospective cohort study. Am J Obstet Gynecol 2011; 204 (2): 139 e1-9
3. Jones HE, Jansson LM, Kaltenbach K. Methadone and perinatal outcomes: another perspective. Am J Obstet Gynecol 2011; 205 (5): e11; author's reply e11-2
4. Jones HE, Jansson LM, O'Grady KE. Maternal treatment with opioid analgesics and risk for birth defects: additional considerations. Am J Obstet Gynecol 2011; 205 (3): e12; author reply e12-3
5. Substance Abuse and Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health: national findings 2009. Office of Applied Studies. HHS publication no. SMA 09-4434. Rockville (MD): Substance Abuse and Mental Health Services Administration, 2010
6. Jones HE, O'Grady KE, Malfi D, et al. Methadone maintenance vs. methadone taper during pregnancy: mater-nal and neonatal outcomes. Am J Addict 2008; 17 (5): 372-86
7. Blinick G, Wallach RC, Jerez E, et al. Drug addiction in pregnancy and the neonate. Am J Obstet Gynecol 1976; 125 (2): 135-42
8. Luty J, Nikolaou V, Bearn J. Is opiate detoxification unsafe in pregnancy? J Subst Abuse Treat 2003; 24 (4): 363-7 (Pubitemid 36809290)
9. Hulse G, O'Neil G. Using naltrexone implants in the management of the pregnant heroin user. Aust N Z J Obstet Gynaecol 2002; 42 (5): 569-73 (Pubitemid 35385713)
10. Hulse GK, Arnol-Reed DE, O'Neil G, et al. Naltrexone implant and blood naltrexone levels over pregnancy. Aust N Z J Obstet Gynaecol 2003; 43 (5): 386-8 (Pubitemid 37304235)
11. Hulse GK, O'Neil G, Arnold-Reed DE. Methadone maintenance vs. implantable naltrexone treatment in the pregnant heroin user. Int J Gynaecol Obstet 2004; 85 (2): 170-1 (Pubitemid 38510235)
12. Hulse GK, O'Neill G. A possible role for implantable naltrexone in the management of the high-risk pregnant heroin user. Aust N Z J Obstet Gynaecol 2002; 42 (1): 93-4 (Pubitemid 34173100)
13. Hulse GK, O'Neill G, Pereira C, et al. Obstetric and neonatal outcomes associated with maternal naltrexone exposure. Aust N Z J Obstet Gynaecol 2001; 41 (4): 424-8 (Pubitemid 33100682)
14. Jones HE, Velez ML, McCaul ME, et al. Specialty treatment for women. In: Strain EC, Stitzer ML, editors. Methadone treatment for opioid dependence. Baltimore (MD): Johns Hopkins University Press, 2006: 455-84
15. US Department of Health and Human Services. National Institutes of Health. Consensus Development Conference Statement. Effective medical treatment of opiate addiction. 1997 Nov 17-19 [online]. Available from URL: http://consensus.nih.gov/1997/1998TreatOpiateAddiction108html. htm [Accessed 2012 Apr 2].
16. Schmid M, Kuessel L, Klein K, et al. First-trimester fetal heart rate in mothers with opioid addiction. Addiction 2010; 105 (7): 1265-8
17. Kandall SR, Albin S, Gartner LM, et al. The narcoticdependent mother: fetal and neonatal consequences. Early Hum Dev 1977; 1 (2): 159-69 (Pubitemid 8224194)
18. Finnegan LP. Treatment issues for opioid-dependent women during the perinatal period. J Psychoactive Drugs 1991; 23 (2): 191-201
19. Finnegan LP. Perinatal substance abuse: comments and perspectives. Semin Perinatol 1991; 15 (4): 331-9
20. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy: effects and management. Obstet Gynecol Clin North Am 1998; 25 (1): 139-51 (Pubitemid 28141705)
21. Jones HE, Haug N, Silverman K, et al. The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. Drug Alcohol Depend 2001; 61 (3): 297-306 (Pubitemid 32119311)
22. Laken MP, Ager JW. Effects of case management on retention in prenatal substance abuse treatment. Am J Drug Alcohol Abuse 1996; 22 (3): 439-48 (Pubitemid 26256212)
23. Svikis DS, Lee JH, Haug NA, et al. Attendance incentives for outpatient treatment: effects in methadone-and nonmethadone-maintained pregnant drug dependent women. Drug Alcohol Depend 1997; 48 (1): 33-41 (Pubitemid 27423626)
24. Finnegan LP, Kaltenbach K. Neonatal abstinence syndrome. In: Hoekelman RA, Adam HM, Nelson NM, et al., editors. Primary pediatric care. St. Louis (MO): Mosby, 1992: 1367-78
25. Connaughton JF, Reeser D, Schut J, et al. Perinatal addiction: outcome and management. Am J Obstet Gynecol 1977; 129 (6): 679-86 (Pubitemid 8241390)
26. Dashe JS, Sheffield JS, Olscher DA, et al. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol 2002; 100 (6): 1244-9 (Pubitemid 35449191)
27. Berghella V, Lim PJ, Hill MK, et al. Maternal methadone dose and neonatal withdrawal. Am J Obstet Gynecol 2003; 189 (2): 312-7
28. Glass L, Evans HE. Narcotic withdrawal in the newborn. Am Fam Physician 1972; 6 (1): 75-8
29. Rajegowda BK, Glass L, Evans HE, et al. Methadone withdrawal in newborn infants. J Pediatr 1972; 81 (3): 532-4
30. Newman RG, Bashkow S, Calko D. Results of 313 consecutive live births of infants delivered to patients in the New York City Methadone Maintenance Treatment Program. Am J Obstet Gynecol 1975; 121 (2): 233-7
31. Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003; (2): CD002209
32. Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2003; (2): CD002207
33. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363 (24): 2320-31
34. Holbrook A, Baxter J, Coyle MG, et al. Characterization of infectious medical complications and comparison of obstetrical outcomes in pregnant opioid-dependent women maintained on methadone or buprenorphine. Addiction. In press
35. McNicholas L, Holbrook A, O'Grady KE. Effect of HCV status on liver enzymes in opioid dependent pregnant women maintained on agonist medication. Addiction. In press
36. Nanovskaya TN, Nekhayeva IA, Hankins GD, et al. Transfer of methadone across the dually perfused preterm human placental lobule. Am J Obstet Gynecol 2008; 198 (1): 126.e1-4
37. Zharikova OL, Deshmukh SV, Nanovskaya TN, et al. The effect of methadone and buprenorphine on human placental aromatase. Biochem Pharmacol 2006; 71 (8): 1255-64 (Pubitemid 43357906)
38. Flynn AM, Kelly J, Mansfield H, et al. A randomized controlled trial of non-stress antepartum cardiotocography. Br J Obstet Gynaecol 1982; 89 (6): 427-33 (Pubitemid 12121531)
39. Lenstrup C, Haase N. Predictive value of antepartum fetal heart rate non-stress test in high-risk pregnancy. Acta Obstet Gynecol Scand 1985; 64 (2): 133-8 (Pubitemid 15127871)
40. Lyons ER, Bylsma-Howell M, Shamsi S, et al. A scoring system for nonstressed antepartum fetal heart rate monitoring. Am J Obstet Gynecol 1979; 133 (3): 242-6 (Pubitemid 9066976)
41. Manning FA, Platt LD, Sipos L. Antepartum fetal evaluation: development of a fetal biophysical profile. Am J Obstet Gynecol 1980; 136 (6): 787-95 (Pubitemid 10156270)
42. Manning FA, Snijders R, Harman CR, et al. Fetal biophysical profile score. VI. Correlation with antepartum umbilical venous fetal pH. Am J Obstet Gynecol 1993; 169 (4): 755-63 (Pubitemid 23317503)
43. Bardakci M, Balci O, Acar A, et al. Comparison of modified biophysical profile and doppler ultrasound in predicting the perinatal outcome at or over 36 weeks of gestation. Gynecol Obstet Invest 2010; 69 (4): 245-50
44. Navaneethakrishnan R, Tutty S, Sinha C, et al. The effect of maternal methadone use on the fetal heart pattern: a computerised CTG analysis. BJOG 2006; 113 (8): 948-50 (Pubitemid 44086922)
45. Ramirez-Cacho WA, Flores S, Schrader RM, et al. Effect of chronic maternal methadone therapy on intrapartum fetal heart rate patterns. J Soc Gynecol Investig 2006; 13 (2): 108-11 (Pubitemid 43155842)
46. Jansson LM, Dipietro J, Elko A. Fetal response to maternal methadone administration. AmJ Obstet Gynecol 2005; 193 (3 Pt 1): 611-7 (Pubitemid 41261452)
47. Wouldes TA, Roberts AB, Pryor JE, et al. The effect of methadone treatment on the quantity and quality of human fetal movement. Neurotoxicol Teratol 2004; 26 (1): 23-34 (Pubitemid 38299106)
48. Jansson LM, Dipietro JA, Velez M, et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicol Teratol 2011 Mar-Apr; 33 (2): 240-3
49. Salisbury AL, Coyle MG, O'Grady KE, et al. Fetal assessment before and after dosing with buprenorphine or methadone. Addiction. In press
50. Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioiddependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005; 79 (1): 1-10 (Pubitemid 41557119)
51. Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006; 101 (2): 275-81 (Pubitemid 43351601)
52. Reprotox [online]. Available fromURL: http://www.reprotox. org [Accessed 2012 Apr 2]
53. Finnegan LP, Connaughton JF Jr, Kron RE, et al. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975; 2 (1-2): 141-58
54. Finnegan LP, Kron RE, Connaughton JF, et al. Assessment and treatment of abstinence in the infant of the drugdependent mother. Int J Clin Pharmacol Biopharm 1975; 12 (1-2): 19-32
55. D'Apolito K, Finnegan L. Assessing signs and symptoms of neonatal abstinence using the Finnegan Scoring Tool, an interobserver reliability program. 2010, Neo Advances [online]. Available fromURL: http://www.neoadvances. com/program. html [Accessed 2012 Apr 2]
56. Stimmel B, Goldberg J, Reisman A, et al. Fetal outcome in narcotic-dependent women: the importance of the type of maternal narcotic used. Am J Drug Alcohol Abuse 1982; 9 (4): 383-95 (Pubitemid 14220501)
57. Doberczak TM, Kandall SR, Friedmann P. Relationship between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal. Obstet Gynecol 1993; 81 (6): 936-40 (Pubitemid 23168737)
58. Doberczak TM, Kandall SR, Wilets I. Neonatal opiate abstinence syndrome in term and preterm infants. J Pediatr 1991; 118 (6): 933-7
59. Blatman S. Methadone effects on pregnancy and the newborn. Proc Natl Conf Methadone Treat 1973; 2: 842-5
60. Kaltenbach K, Finnegan LP. Perinatal and developmental outcome of infants exposed to methadone in-utero. NIDA Res Monogr 1987; 76: 276
61. Kaltenbach KA. Exposure to opiates: behavioral outcomes in preschool and school-age children. NIDA Res Monogr 1996; 164: 230-41
62. Lejeune C, Simmat-Durand L, Gourarier L, et al. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend 2006; 82 (3): 250-7
63. Marquet P, Lavignasse P, Gaulier J-M, et al. Case study of neonates born to mothers undergoing buprenorphine maintenance treatment. In: Kintz P, Marquet P, editors. Buprenorphine therapy of opiate addiction. Totowa (NJ): Humana Press, 2002: 123-35
64. No authors listed. Meprobamate and chlordiazepoxide, teratogenic effect? [in Danish]. Ugeskr Laeger 1975; 137 (18): 1017-8
65. Winklbaur B, Baewert A, Jagsch R, et al. Association between prenatal tobacco exposure and outcome of neonates born to opioid-maintained mothers. Implications for treatment. Eur Addict Res 2009; 15 (3): 150-6
66. Lipsitz PJ. A proposed narcotic withdrawal score for use with newborn infants: a pragmatic evaluation of its efficacy. Clin Pediatr (Phila) 1975; 14 (6): 592-4
67. Gaalema DE, Scott TL, Heil SH, et al. Differences in the profile of neonatal abstinence syndrome signs in methadonevs. buprenorphine-exposed neonates. Addiction. In press
68. Coyle MG, Salibury AL, Lester BM, et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction. In press
69. Blinick G. Menstrual function and pregnancy in narcotics addicts treated with methadone. Nature 1968; 219 (5150): 180
70. Finnegan LP, Kandall SR. Maternal and neonatal effects of alcohol and drugs. In: Lowinson JH, Ruiz P, Millman RB, et al., editors. Substance abuse: a comprehensive textbook. 4th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2005
71. Pond SM, Kreek MJ, Tong TG, et al. Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther 1985; 233 (1): 1-6 (Pubitemid 15083518)
72. Franck LS, Harris SK, Soetenga DJ, et al. The Withdrawal Assessment Tool-1 (WAT-1): an assessment instrument for monitoring opioid and benzodiazepine withdrawal symptoms in pediatric patients. Pediatr Crit Care Med 2008; 9 (6): 573-80
73. Abrahams RR, Kelly SA, Payne S, et al. Rooming-in compared with standard care for newborns of mothers using methadone or heroin. Can Fam Physician 2007; 53 (10): 1722-30 (Pubitemid 351194540)
74. Abrahams RR, MacKay-Dunn MH, Nevmerjitskaia V, et al. An evaluation of rooming-in among substance-exposed newborns in British Columbia. J Obstet Gynaecol Can 2010; 32 (9): 866-71
75. Weiner SM, Finnegan LP. Drug withdrawal in the neonate. In: Carter B, Gardner S, editors. Handbook of neonatal intensive care. St. Louis (MO): Mosby, 2010
76. Eschenroeder AC, Vestal-Laborde AA, Sanchez ES, et al. Oligodendrocyte responses to buprenorphine uncover novel and opposing roles of mu-opioid-and nociceptin/orphanin FQ receptors in cell development: implications for drug addiction treatment during pregnancy. Glia 2012; 60 (1): 125-36
77. Sanchez ES, Bigbee JW, Fobbs W, et al. Opioid addiction and pregnancy: perinatal exposure to buprenorphine affects myelination in the developing brain. Glia 2008; 56 (9): 1017-27
78. Back SE, Contini R, Brady KT. Substance abuse in women: does gender matter? Psychiatric Times 2006; 24 (1)
79. Finnegan LP. Introduction to women, children and addiction. J Addict Dis 2010; 29 (2): 113-6